Mark Snyder Net Worth

The estimated Net Worth of Mark Howard Snyder is at least $847 Thousand dollars as of 16 February 2024. Mr Snyder owns over 4,796 units of Halozyme Therapeutics stock worth over $846,723 and over the last 3 years he sold HALO stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Snyder HALO stock SEC Form 4 insiders trading

Mr has made over 3 trades of the Halozyme Therapeutics stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 4,796 units of HALO stock worth $284,834 on 16 February 2024.

The largest trade he's ever made was exercising 7,611 units of Halozyme Therapeutics stock on 3 January 2024 worth over $452,017. On average, Mr trades about 2,860 units every 58 days since 2022. As of 16 February 2024 he still owns at least 14,257 units of Halozyme Therapeutics stock.

You can see the complete history of Mr Snyder stock trades at the bottom of the page.

Mr. Mark Snyder biography

Mark Snyder is the Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. at Halozyme Therapeutics.

What's Mr Snyder's mailing address?

Mark's mailing address filed with the SEC is C/O HALOZYME THERAPEUTICS, INC., 12390 EL CAMINO REAL, SAN DIEGO, CA, 92130.

Insiders trading at Halozyme Therapeutics

Over the last 18 years, insiders at Halozyme Therapeutics have traded over $92,345,799 worth of Halozyme Therapeutics stock and bought 9,720,772 units worth $67,958,365 . The most active insiders traders include Randal J Kirk, David A Ramsay, and Gregory Ian Frost. On average, Halozyme Therapeutics executives and independent directors trade stock every 21 days with the average trade being worth of $3,961,432. The most recent stock trade was executed by Michael J. La Barre on 27 August 2024, trading 5,580 units of HALO stock currently worth $102,728.

What does Halozyme Therapeutics do?

we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies

Complete history of Mr Snyder stock trades at Halozyme Therapeutics

Halozyme Therapeutics executives and stock owners

Halozyme Therapeutics executives and other stock owners filed with the SEC include:

• Helen Torley,
  President, Chief Executive Officer, Director
• Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.,
  Pres, CEO & Director
• Elaine D. Sun,
  Sr. VP & CFO
• Dr. Michael J. LaBarre,
  Sr. VP & Chief Technical Officer
• Connie Matsui,
  Independent Chairman of the Board
• Jeffrey Henderson,
  Independent Director
• Kenneth Kelley,
  Independent Director
• Matthew Posard,
  Independent Director
• Bernadette Connaughton,
  Independent Director
• Jean-Pierre Bizzari,
  Independent Director
• James Daly,
  Independent Director
• Al Kildani,
  Vice President, Investor Relations & Corporate Communications
• Elaine Sun,
  Chief Financial Officer, Senior Vice President
• Todd Butler,
  Chief of Staff to the CEO, VP & Head of Project Management
• Dr. Steve Knowles B.S.,
  Chief Medical Officer
• William J. Fallon,
  Sr. VP &, Global ENHANZE Program Lead, CMC Operations & Strategic Alliances
• Amy Marinne Fox,
  VP of HR
• Mark Snyder,
  Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• Albert S. Kildani,
  VP of Investor Relations & Corp. Communications
• Ed Gemo,
  VP, Chief Information & Security Officer
• Athena Countouriotis,
  SVP and Chief Medical Officer
• Kathryn E Falberg,
  Director
• Mark J Gergen,
  SVP, Chief Operating Officer
• Mark Howard Snyder,
  SVP, CHIEF LEGAL OFFICER
• Randal J Kirk,
  Director
• Harry J Leonhardt,
  SVP, GC and CCO
• Alison A. Armour,
  SVP, Research & Development
• John Stuart Patton,
  Director
• Robert Engler,
  Director
• David A Ramsay,
  Secretary, CFO
• William J Fallon,
  VP-Manufacturing and Operation
• James P Shaffer,
  VP & Chief Commercial Officer
• Jean I Liu,
  VP & General Counsel
• Gregory Ian Frost,
  VP and Chief Scientific Off.
• H. Michael Shepard,
  VP, Chief Scientific Officer
• Kurt A Gustafson,
  Vice President and CFO
• Steven T Thornton,
  Director
• Jonathan E Lim,
  President, CEO
• Richard C Yocum,
  VP-Clinical Development
• Jonathan A Leff,
  VP, Chief Medical Officer
• Robert J Little,
  VP-Chief Commercial Officer
• Don A Kennard,
  Vice President, Regulatory Aff
• Matthew Hooper,
  Vice Pres & General Counsel
• Benjamin Hickey,
  SVP, Chief Commerical Officer
• Laurie Stelzer,
  SVP, Chief Financial Officer
• Mahesh Krishnan,
  
• Masaru Matsuda,
  SVP, General Counsel
• Akiko Moni Miyashita,
  
• Michael J. La Barre,
  SVP, CHIEF TECHNICAL OFFICER
• Nicole La Brosse,
  SVP, CHIEF FINANCIAL OFFICER
• Barbara Gayle Duncan,